Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

News from NCI

  • Lung-MAP Launches: First Precision Medicine Trial From National Clinical Trials Network
    NCI Press Release

    (Posted: 06/16/2014) - A unique public-private collaboration today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial, a multi-drug, multi-arm, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer.
    View the article in Spanish

  • NCI at ASCO: A brief overview on research in women's cancers
    NCI Perspective Article

    (Posted: 06/02/2014) - The 2014 annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June highlighted results from a number of NCI-supported and -sponsored clinical trial results in women’s cancers. Taken together, these results represent important advances in our understanding of how to treat these diseases and improve the lives of those living with them.
    View the article in Spanish

  • New treatment option for young women with hormone-sensitive breast cancer
    NCI Press Release

    (Posted: 06/01/2014) - A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.
    View the article in Spanish

  • Color drawing of internal organs in a man’s midsection, with prostate, bladder and rectum noted. Prostate is at mid-center of the bottom of the image.
    NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy
    NCI Press Release

    (Posted: 12/05/2013, Updated: 06/01/2014) - Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a NIH-supported randomized controlled clinical trial.
    View the article in Spanish

  • Image of pills spilling out of a bottle, next to a glass of water and a blood pressure monitor and cuff
    Clinical trial analysis suggests drug combination may be highly effective in recurrent ovarian cancer
    NCI Press Release

    (Posted: 05/31/2014) - Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago. The trial compared the activity of a combination of the drug olaparib and the blood vessel inhibitor drug cediranib vs. olaparib alone. Trial results showed a near doubling of progression-free survival benefit for the combination therapy over use of the single drug alone.
    View the article in Spanish

  • Treatment helps young women preserve their fertility during breast cancer chemotherapy
    NCI Press Release

    (Posted: 05/30/2014) - Researchers have found that young women with breast cancer were able to better preserve their fertility during cancer treatments by using hormone-blocking drug injections that put them into temporary menopause. The results announced today at the annual meeting of the American Society of Clinical Oncology in Chicago are from the Prevention of Early Menopause Study (POEMS), a clinical trial sponsored by NCI.
    View the article in Spanish

  • Black and white scan of patients lung, before (left) and after (right) treatment. Right image shows arrows pointing to metastatic tumors that have shrunk.
    NIH study demonstrates that a new cancer immunotherapy method could be effective against a wide range of cancers
    NCI Press Release

    (Posted: 05/08/2014) - A new method for using immunotherapy to specifically attack tumor cells that have mutations unique to a patient’s cancer has been developed by NCI scientists.

  • A xenograph model of green fluorescent protein of breast cancer cells implanted in the mammary fat pad of female nude mouse. The slide that shows NOS2 being targeted with drug; the slide background is black and  NOS2 appears in orange and purple blotches.
    Study in mice shows that an aggressive type of breast cancer is linked to an inflammatory protein
    NCI News Note

    (Posted: 04/14/2014) - Aberrant expression of an inflammatory protein, nitric oxide synthase 2 (NOS2), may enhance the progression and metastasis of an aggressive and less common form of breast cancer, known as the estrogen receptor-negative type of disease.

  • An Open Letter to the Cancer Community Regarding Community Clinical Trials

    (Posted: 04/11/2014) - The National Cancer Institute (NCI) is in the process of combining its two community-based research networks to create a single network that builds on the strengths of the Community Clinical Oncology Program/Minority-Based Community Clinical Oncology Program (CCOPs) and the NCI Community Cancer Centers Program (NCCCP).

  • NCI intramural research highlighted at 2014 AACR meeting
    NCI Perspective Article

    (Posted: 04/07/2014) - This year’s American Association for Cancer Research meeting featured plenary talks by two NCI scientists, Steven Rosenberg, M.D., and Louis Staudt, M.D., Ph.D., that highlighted the challenges in developing varied and potentially synergistic treatments for aggressive forms of cancer. Each researcher has been focusing primarily on a particularly difficult to treat cancer (melanoma and lymphoma, respectively) for many decades, and their presentations highlight the diligence and tenacity needed to come to a better understanding of the cancer process and to find effective agents to target the diseases they study.

< Previous  1 2 3 4 5 6 7 8 9 10  Next >
  • Posted: August 13, 2012
  • Updated: August 13, 2012